Bora Chae1, Jesse J Jung2, Sarah Mrejen3, Roberto Gallego-Pinazo4, Nicolas A Yannuzzi5, Samir N Patel5, Christine Y Chen6, Marcela Marsiglia7, Sucharita Boddu8, K Bailey Freund2. 1. Department of Ophthalmology New York University School of Medicine, New York, New York, United States 2Vitreous Retina Macula Consultants of New York, New York, New York, United States. 2. Department of Ophthalmology New York University School of Medicine, New York, New York, United States 2Vitreous Retina Macula Consultants of New York, New York, New York, United States 3LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Thr. 3. Vitreous Retina Macula Consultants of New York, New York, New York, United States 3LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States. 4. Vitreous Retina Macula Consultants of New York, New York, New York, United States 3LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States 5Department of Ophthalmology, University and Polytechni. 5. Weill Cornell Medical College, New York, New York, United States. 6. Vitreous Retina Macula Consultants of New York, New York, New York, United States 3LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States 7Department of Surgery, Monash University, Melbourne, A. 7. Vitreous Retina Macula Consultants of New York, New York, New York, United States 3LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States 4Edward S. Harkness Eye Institute, Columbia University. 8. Department of Ophthalmology New York University School of Medicine, New York, New York, United States.
Abstract
PURPOSE: To examine the baseline factors associated with good (20/60 or better) versus poor (20/200 or worse) visual outcomes in eyes with treatment-naïve neovascular age-related macular degeneration (AMD) receiving intravitreal antivascular endothelial growth factor (VEGF) on a treat-and-extend regimen (TER). METHODS: An observational, retrospective series of patients managed with a TER, identified as having either good or poor visual outcomes, was examined. A multivariate regression analysis of baseline characteristics identified factors associated with good and poor vision at 2, 3, and 4 years. Neovascular subtypes were identified using fluorescein angiography (FA) alone and the anatomic classification system with FA and optical coherence tomography (OCT). RESULTS: One hundred thirty-eight patients (154 eyes) fit the inclusion criteria at 2 years, 106 patients (113 eyes) at 3 years, and 72 patients (74 eyes) at 4 years. In the multivariate analysis, type 1 lesions, according to anatomic classification, had better vision at 24 months (95% CI: [3.1, 82.7], P = 0.01), 36 months (95% CI: [1.97, 24.17], P = 0.003), and 48 months (95% CI: [2.01, 65.47], P = 0.006). Clopidogrel use was associated with poor vision at 24 months (95% CI: [0.03, 0.68], P = 0.013). Vision at 3 months was the best predictor of vision at year 4 (β = -4.277, P = 0.002). CONCLUSIONS: Eyes with neovascular AMD managed with a TER of anti-VEGF therapy having type 1 neovascularization at baseline were more likely to maintain good vision over 4 years, whereas clopidogrel use predicted poor vision at 2 years. Vision at 3 months was the best predictor for favorable long-term vision.
PURPOSE: To examine the baseline factors associated with good (20/60 or better) versus poor (20/200 or worse) visual outcomes in eyes with treatment-naïve neovascular age-related macular degeneration (AMD) receiving intravitreal antivascular endothelial growth factor (VEGF) on a treat-and-extend regimen (TER). METHODS: An observational, retrospective series of patients managed with a TER, identified as having either good or poor visual outcomes, was examined. A multivariate regression analysis of baseline characteristics identified factors associated with good and poor vision at 2, 3, and 4 years. Neovascular subtypes were identified using fluorescein angiography (FA) alone and the anatomic classification system with FA and optical coherence tomography (OCT). RESULTS: One hundred thirty-eight patients (154 eyes) fit the inclusion criteria at 2 years, 106 patients (113 eyes) at 3 years, and 72 patients (74 eyes) at 4 years. In the multivariate analysis, type 1 lesions, according to anatomic classification, had better vision at 24 months (95% CI: [3.1, 82.7], P = 0.01), 36 months (95% CI: [1.97, 24.17], P = 0.003), and 48 months (95% CI: [2.01, 65.47], P = 0.006). Clopidogrel use was associated with poor vision at 24 months (95% CI: [0.03, 0.68], P = 0.013). Vision at 3 months was the best predictor of vision at year 4 (β = -4.277, P = 0.002). CONCLUSIONS: Eyes with neovascular AMD managed with a TER of anti-VEGF therapy having type 1 neovascularization at baseline were more likely to maintain good vision over 4 years, whereas clopidogrel use predicted poor vision at 2 years. Vision at 3 months was the best predictor for favorable long-term vision.
Authors: Emma C Zanzottera; Thomas Ach; Carrie Huisingh; Jeffrey D Messinger; K Bailey Freund; Christine A Curcio Journal: Retina Date: 2016-12 Impact factor: 4.256
Authors: Thibaud Mathis; Frank G Holz; Sobha Sivaprasad; Young Hee Yoon; Nicole Eter; Lee-Jen Chen; Adrian Koh; Eduardo Cunha de Souza; Giovanni Staurenghi Journal: Eye (Lond) Date: 2022-09-14 Impact factor: 4.456
Authors: F Ziemssen; N Feltgen; F G Holz; R Guthoff; A Ringwald; T Bertelmann; A Wiedon; C Korb Journal: BMC Ophthalmol Date: 2017-01-19 Impact factor: 2.209
Authors: Georges Azar; Benjamin Wolff; Flore De Bats; Jeremie Halfon; Mate Streho; Sarah Tick; Laurent Castelnovo; Guillaume Michel; Helene Masse; Vivien Vasseur; Marwan Sahyoun; Martine Mauget-Faÿsse Journal: Biomed Res Int Date: 2018-06-26 Impact factor: 3.411